CWBHF Quote, Financials, Valuation and Earnings

NanoViricides, Inc. has a net margin of -50.58% compared to Charlotte's Web Holdings, Inc.'s net margin of --. Charlotte's Web Holdings, Inc.'s return on equity of -105.72% beat NanoViricides, Inc.'s return on equity of -92.29%.

Charlotte's Web Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 138.1%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 473.77%. Given that NanoViricides, Inc. has higher upside potential than Charlotte's Web Holdings, Inc., analysts believe NanoViricides, Inc. is more attractive than Charlotte's Web Holdings, Inc..

Charlotte's Web Holdings, Inc. has a beta of 1.359, which suggesting that the stock is 35.86% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.

Charlotte's Web Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charlotte's Web Holdings, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.

Charlotte's Web Holdings, Inc. quarterly revenues are $11.5M, which are larger than NanoViricides, Inc. quarterly revenues of --. Charlotte's Web Holdings, Inc.'s net income of -$5.8M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Charlotte's Web Holdings, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charlotte's Web Holdings, Inc. is 0.34x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -50.58% compared to Charlotte's Web Holdings, Inc.'s net margin of --. Charlotte's Web Holdings, Inc.'s return on equity of -105.72% beat Oragenics, Inc.'s return on equity of -509.23%.

Charlotte's Web Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 138.1%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 134.85%. Given that Charlotte's Web Holdings, Inc. has higher upside potential than Oragenics, Inc., analysts believe Charlotte's Web Holdings, Inc. is more attractive than Oragenics, Inc..

Charlotte's Web Holdings, Inc. has a beta of 1.359, which suggesting that the stock is 35.86% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Charlotte's Web Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charlotte's Web Holdings, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Charlotte's Web Holdings, Inc. quarterly revenues are $11.5M, which are larger than Oragenics, Inc. quarterly revenues of --. Charlotte's Web Holdings, Inc.'s net income of -$5.8M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Charlotte's Web Holdings, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charlotte's Web Holdings, Inc. is 0.34x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -50.58% compared to Charlotte's Web Holdings, Inc.'s net margin of --. Charlotte's Web Holdings, Inc.'s return on equity of -105.72% beat Palatin Technologies's return on equity of --.

Charlotte's Web Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 138.1%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Charlotte's Web Holdings, Inc., analysts believe Palatin Technologies is more attractive than Charlotte's Web Holdings, Inc..

Charlotte's Web Holdings, Inc. has a beta of 1.359, which suggesting that the stock is 35.86% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Charlotte's Web Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charlotte's Web Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Charlotte's Web Holdings, Inc. quarterly revenues are $11.5M, which are larger than Palatin Technologies quarterly revenues of --. Charlotte's Web Holdings, Inc.'s net income of -$5.8M is higher than Palatin Technologies's net income of --. Notably, Charlotte's Web Holdings, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charlotte's Web Holdings, Inc. is 0.34x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -50.58% compared to Charlotte's Web Holdings, Inc.'s net margin of --. Charlotte's Web Holdings, Inc.'s return on equity of -105.72% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Charlotte's Web Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 138.1%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than Charlotte's Web Holdings, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Charlotte's Web Holdings, Inc..

Charlotte's Web Holdings, Inc. has a beta of 1.359, which suggesting that the stock is 35.86% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Charlotte's Web Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charlotte's Web Holdings, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Charlotte's Web Holdings, Inc. quarterly revenues are $11.5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Charlotte's Web Holdings, Inc.'s net income of -$5.8M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Charlotte's Web Holdings, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charlotte's Web Holdings, Inc. is 0.34x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.